Among the goals of the Department of Health and Human Services and the Food and Drug Administration (FDA) is to improve written communication to patients about their prescription medicines. Bristol-Myers Squibb Company recognizes the need for patients to receive high-quality information regarding their therapeutic options. The company has initiated a program to prepare patient-oriented labeling for certain prescription products for which such material is appropriate, using the FDA's proposed Medication Guide as a basis for content and format.
Steering Committee for the Collaborative Development of a Long-Range Action Plan for the Provision of Useful Prescription Medicine Information.Action Plan for the Provision of Useful Prescription Medicine Information. December 1996: 11.
6.
Federal Register.1979;44:40016.
7.
Federal Register.1980;45:60754.
8.
Federal Register.1981;46:13193.
9.
Federal Register.1981;46:23739.
10.
Federal Register.1982;47:39147.
11.
Federal Register.1995;60:44182.
12.
HR 104–180.
13.
Federal Register.1995;60:44199.
14.
Steering Committee for the Collaborative Development of a Long-Range Action Plan for the Provision of Useful Prescription Medicine Information.Action Plan for the Provision of Useful Prescription Medicine Information. December 1996: 3.
15.
Federal Register.1998;63:66378–66400.
16.
JonesSPatient information leaflets for HIV positive patients. Pharmaceut J. Sep 8, 1990;245: 308–309.
17.
FleckensteinLOral contraceptive patient information—a questionnaire study of attitudes, knowledge, and preferred information sources. JAMA.1976;235(13):1331–1336.
18.
SmithD. Compliance packaging: a patient education tool. Am Pharmacy. Feb 2, 1989;NS29(2):126–137.
19.
KuperbergJRAll in one: the user-friendly rx product. Pharmaceut Exec. April 1990:74–78.
20.
GibbsSThe benefits of prescription information leaflets (1). Br J Clin Pharmacol.1989;27:723–739.
21.
GeorgeCFPrescription information leaflets: a pilot study in general practice. Brit Med J1983;287:1193–1196.
22.
GlazierRWritten patient information about triple-marker screening: a randomized, controlled trial. Obstet Gynecol. November 1997;90(5):769–774.
23.
National Institute of Health. Minimizing Medical Product Errors, A Systems Approach, Bethesda, MD; Jan. 8, 1998.
24.
SlessDWisemanR. Writing about Medicines for People—Usability Guidelines for Consumer Medicine Information. 2nd ed.Communication Research Institute of Australia. Dickson, Australia. Ch 6, 73–96, Appendices 3, 4, 5, 121–157.
